Drug news
NICE recommends Spinraza for the treatment of spinal muscular atrophy
Biogen Inc.has announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for Spinraza (nusinersen) on the National Health Service (NHS).
The positive recommendation is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3. SMA is a rare, debilitating and life-threatening disease that results in severe, progressive muscular atrophy and weakness.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.